Patents by Inventor Carla Cerami

Carla Cerami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130102530
    Abstract: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.
    Type: Application
    Filed: June 13, 2012
    Publication date: April 25, 2013
    Applicant: The Kenneth S. Warren Institute, Inc.
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Patent number: 8404226
    Abstract: Methods and compositions are provided for treating a mammal having inflammation by protecting or enhancing a responsive cell, tissue, organ or body part exhibiting or associated with the inflammation, by systemic or local administration of a composition comprising a tissue protective cytokine. The invention also encompasses combination treatments comprising administering a composition comprising a tissue protective cytokine of the invention and administering at least one anti-inflammatory or least one immunomodulatory agent.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: March 26, 2013
    Assignee: The Kenneth S. Warren Institute, Inc.
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Publication number: 20120142589
    Abstract: Methods and compositions are provided for protecting or enhancing a responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of a tissue protective cytokine.
    Type: Application
    Filed: August 1, 2011
    Publication date: June 7, 2012
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Publication number: 20110245169
    Abstract: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.
    Type: Application
    Filed: February 28, 2011
    Publication date: October 6, 2011
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Patent number: 7767643
    Abstract: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: August 3, 2010
    Assignee: The Kenneth S. Warren Institute, Inc.
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Publication number: 20090233844
    Abstract: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.
    Type: Application
    Filed: November 19, 2008
    Publication date: September 17, 2009
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Publication number: 20090004202
    Abstract: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.
    Type: Application
    Filed: May 20, 2008
    Publication date: January 1, 2009
    Inventors: MICHAEL BRINES, Anthony Cerami, Carla Cerami Hand
  • Patent number: 7410941
    Abstract: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: August 12, 2008
    Assignee: The Kenneth S. Warren Institute, Inc.
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Patent number: 7345019
    Abstract: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: March 18, 2008
    Assignee: The Kenneth S. Warren Institute, Inc.
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Publication number: 20080014193
    Abstract: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.
    Type: Application
    Filed: August 14, 2007
    Publication date: January 17, 2008
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Publication number: 20070298031
    Abstract: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.
    Type: Application
    Filed: July 26, 2007
    Publication date: December 27, 2007
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami Hand
  • Patent number: 7309687
    Abstract: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: December 18, 2007
    Assignee: The Kenneth S. Warren Institute, Inc.
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Publication number: 20060034799
    Abstract: Methods and compositions are provided for treating a mammal having inflammation by protecting or enhancing a responsive cell, tissue, organ or body part exhibiting or associated with the inflammation, by systemic or local administration of a composition comprising a tissue protective cytokine. The invention also encompasses combination treatments comprising administering a composition comprising a tissue protective cytokine of the invention and administering at least one anti-inflammatory or least one immunomodulatory agent.
    Type: Application
    Filed: July 3, 2003
    Publication date: February 16, 2006
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Publication number: 20050176627
    Abstract: Methods for increasing the hematocrit of an individual while maintaining the tissue protective activities of endogenous erythropoietin through the administration of a pharmaceutical compound containing chemically modified long acting erythropoietin. Also disclosed are the new chemically modified long acting erythropoietins, methods of producing the chemically modified long acting erythropoietins, and compositions comprising the chemically modified long acting erythropoietins.
    Type: Application
    Filed: March 9, 2005
    Publication date: August 11, 2005
    Inventors: Anthony Cerami, John Smart, Michael Brines, Carla Cerami
  • Publication number: 20040166141
    Abstract: The present invention provides methods and devices for inducing, stimulating, blocking and reducing the immune response of a mammal to an antigen, using an implantable device which exposes the antigen in a controlled fashion to cells of the immune system. The device comprises a porous matrix contained within a perforated, impermeable container. By manipulating the bioavailability of antigen within the device, and the timing of introduction of antigen into the device relative to the time of implantation of the device within the mammal, a robust and long-term response can be induced against an antigen, or an existing or potential immune response can be down regulated or blocked. The methods and devices can be used for therapeutic vaccination, and in non-exposed mammals for prophylactic vaccination. Immunity can be cellular, humoral, or mucosal.
    Type: Application
    Filed: February 20, 2004
    Publication date: August 26, 2004
    Inventors: Anthony Cerami, Carla Cerami, Cohava Gelber, David Dove
  • Publication number: 20040122216
    Abstract: Methods and compositions are provided for protecting or enhancing a responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an recombinant tissue protective cytokine.
    Type: Application
    Filed: July 1, 2003
    Publication date: June 24, 2004
    Inventors: Jacob Nielsen, Jan Torleif Pedersen, Jens Gerwien, Katrine Bay, Lars Ostergaard Pedersen, Marcel Leist, Marie Aavang Geist, Pekka Kallunki, Soren Christensen, Thomas Sager, Michael Brines, Anthony Cerami, Carla Cerami
  • Patent number: 6615842
    Abstract: This invention provides methods, devices and agents for the removal of nucleophilic toxins present in tobacco and tobacco smoke. The filter element of a tobacco smoking device or an air filtration device used in conjunction with a tobacco smoking device may comprise chemical moieties reactive with nucleophilic compounds, or agents that trap nucleophilic compounds may be incorporated into the filter element of tobacco smoking device such as a cigarette, cigar, pipe, or in a separate filter through which tobacco smoke passes before entering the mouth. The agents may also be incorporated into air filters for removing tobacco combustion product toxins from room air. The agents may also be incorporated into smoking or smokeless tobacco to remove toxins.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: September 9, 2003
    Assignee: Cerami Consulting Corp.
    Inventors: Anthony Cerami, Carla Cerami, Peter Ulrich
  • Publication number: 20030134798
    Abstract: Methods and compositions are provided for protecting or enhancing erythropoietin-responsive cell, tissue, organ and bodily part function and viability in vivo, in situ or ex vivo in mammals including human beings by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin.
    Type: Application
    Filed: January 24, 2003
    Publication date: July 17, 2003
    Applicant: The Kenneth Warren Institute, Inc.
    Inventors: Michael Brines, Anthony Cerami, Carla Cerami
  • Publication number: 20030118630
    Abstract: The present invention is directed to an implantable immune modulation device that is useful for modulating an immune response in mammals, comprising a plurality of fibers, within a porous shell. The fiber filling is loaded with single or multiple antigens, and optionally one or more biologically active compounds such as cytokines (e.g. lymphokines, chemokines etc.), attachment factors, genes, peptides, proteins, nucleotides, carbohydrates or cells depending on the application.
    Type: Application
    Filed: December 7, 2001
    Publication date: June 26, 2003
    Inventors: Anthony Cerami, Carla Cerami, Qiao-wen Xie, Kevor S. TenHuisen, Joel Rosenblatt, Ilya S. Koyfman
  • Publication number: 20030119733
    Abstract: There is provided peptide and mimetic inhibitors for the binding of a circumsporozoite polypeptide to receptors of hepatocytes from malaria-susceptible mammals. Also contemplated is a method of inhibiting the binding of a malaria sporozoites to hepatocytes susceptible to sporozoite invasion. A peptide of Region II+ of the circumsporozoite protein is also provided, as is a method of targeting the delivery of substances to hepatocytes.
    Type: Application
    Filed: March 14, 2002
    Publication date: June 26, 2003
    Applicant: New York University
    Inventors: Carla Cerami, Ute Frevert, Photini Sinnis, Victor Nussenzweig